database / healing
TB-500
also known as thymosin β4 fragment (17-23)
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 62707662. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
LKKTETQ
Leu-Lys-Lys-Thr-Glu-Thr-Gln
- hydrophobic
- positive
- negative
- polar
- aromatic
- glycine
- proline
- cysteine
Modified molecule. N-terminally acetylated. The build-time mass check flagged this: the bare LKKTETQ backbone computes to 847.0 Da against PubChem's 889.0 Da — a difference of exactly 42.0 Da, the mass of an acetyl group. The sequence is right; the molecule carries an N-terminal acetyl.
Backbone carries modifications, so computed backbone mass is not comparable to the reported mass of the complete molecule.
Molecular data
| molecular formula | C38H68N10O14 |
|---|---|
| molecular weight | 889 Da (PubChem) |
| computed backbone mass | 846.98 Da |
| length | 7 residues |
| net charge (pH 7.4) | +1 |
| mean hydropathy | -1.77 |
| half-life | not characterised |
| delivery route | not characterised |
| PubChem CID | 62707662 |
| PDB | not characterised |
| UniProt parent | P62328 |
Mechanism
Actin-binding fragment of thymosin β4; the LKKTETQ motif is the actin-binding region described in the literature.
Reported targets: G-actin
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Position in the parent protein
MSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
Parent sequence from UniProt P62328. TB-500 corresponds to the actin-binding fragment of thymosin β4.
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| tissue repair | Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopat… Joint diseases and related surgery 2026 |
| cell migration | Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskele… Preprints.org 2026 |
| angiogenesis | Peptide Supplements and Their Therapeutic Applications in Sports Medicine The American journal of sports medicine 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT07487363 | TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | RECRUITING | PHASE1, PHASE2 |
Literature (8)
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study — Joint diseases and related surgery 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42542926 · DOI 10.52312/jdrs.2026.2951
Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202605.1124.v1
Peptide Supplements and Their Therapeutic Applications in Sports Medicine — The American journal of sports medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42578445 · DOI 10.1177/03635465261464420
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — Frontiers in aging 2026
BackgroundPeptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.ObjectiveTo comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.MethodsA comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume…
open access ↗ · PMID 42021992 · DOI 10.3389/fragi.2026.1790247
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro — Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2024
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 38382158 · DOI 10.1016/j.jchromb.2024.124033
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management — Current pain and headache reports 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42635865 · DOI 10.1007/s11916-026-01542-z
Comparative effects of dietary sodium butyrate and tributyrin on broiler chickens' performance, gene expression, intestinal histomorphometry, blood indices, and litter — Scientific reports 2025
Sodium butyrate and tributyrin are known to enhance broiler chicken performance. In this study, 1,000 Arbor Acres broiler chicks were assigned to four dietary treatments (250 birds each; six replicates of 40-42 birds): a control basal diet (CON), or the same diet supplemented with either 500 g/ton tributyrin (40%) + copper + essential oils (TB-500), 300 g/ton di- and tri-butyrin (60%) (TB-300), or 500 g/ton coated sodium butyrate (40%) (SB-500). Weekly growth parameters were recorded, and on Day 35, carcass traits, serum biochemistry, immunity, gene expression (mTOR, TLR4, NBN), intestinal morphology, caecal microbiota, and litter hygiene were assessed. TB-300 improved body weight (+ 4.6%, P = 0.014), FCR (- 5.2%, P = 0.032), and European Production Efficiency Factor (EPEF) (+ 14.9%, P = 0.006). SB-500 significantly reduced litter Clostridia (P < 0.0001) and aerobic bacteria (P = 0.026) …
open access ↗ · PMID 40681595 · DOI 10.1038/s41598-025-09278-3
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41476424 · DOI 10.1177/03635465251357593
Related
BPC-157
healing · 8 citations
Thymosin β4
healing · 8 citations
GHK
healing · 8 citations
Larazotide
healing · 3 citations